Why some peptides are still Category 2 after the 2026 reclassification news
Headlines move fast. Federal Register notices do not.
TL;DR
- The February 2026 HHS announcement and the April 2026 reclassification path signaled change, but several peptides remain in FDA Category 2 pending formal Federal Register action.
- Category 2 means a peptide is generally not available through 503A compounding pharmacies until the FDA completes its review.
- Status can change with each new Federal Register notice. Patients and clinicians should check the current FDA list, not last week's news cycle.
What it is
The FDA maintains two lists for substances 503A compounding pharmacies may use as bulk drug substances. Category 1 includes substances eligible for compounding. Category 2 includes substances under review for safety or effectiveness concerns (FDA Bulk Drug Substances List 1 — 503A). A peptide in Category 2 cannot be used by a 503A pharmacy to prepare patient-specific prescriptions until it is moved to Category 1.
How it works
Picture a long staircase with two landings. Category 1 is the upper landing — peptides on it can be compounded for patients. Category 2 is the lower landing — peptides there are waiting on a review. Moving from Category 2 to Category 1 requires a formal Federal Register notice, not a press release. The HHS February 2026 announcement was a strong signal but not a notice. The April 2026 reclassification path moved several peptides up the stairs. Others are still in line.
Who asks about it
People usually ask this question after reading a headline that sounded like everything had changed and finding their compound of interest still unavailable. The disconnect between news coverage and Federal Register reality is real — and worth understanding before booking a clinician appointment expecting access.
What the literature and federal record show
As of mid-2026, peptides commonly cited as still in Category 2 included BPC-157, TB-500, KPV, MOTS-c, DSIP, epitalon, Selank, Semax, and melanotan-2. The April 2026 reclassification path moved 12 peptides from restriction to availability; that left a meaningful subset still under review. Each peptide is evaluated separately — manufacturing standards, identity testing, and safety review proceed compound by compound (Federal Register, FDA notices).
What to know before considering it
Always check the current FDA Category 1 list before assuming a peptide is available through a 503A pharmacy. Status changes are public but not always promoted. A clinician's prescription cannot create access for a peptide that 503A pharmacies cannot legally compound.
The Halftime POV
Reclassification news cycles move faster than regulatory action. The honest read: progress is real and partial. The right answer when a peptide of interest is still Category 2 is patience plus accuracy — not a workaround through gray-market sources.
Related reading:
- Category 1 vs Category 2 peptides: the access framework
- The February 2026 HHS announcement on peptide reclassification
- The 12 peptides removed from FDA restriction in 2026
FAQ
Q: What does Category 2 mean for peptide access? A: Category 2 means a substance has been nominated for the FDA's 503A bulk drug substance list but the FDA has identified concerns about safety or effectiveness that require further review. While a peptide sits in Category 2, 503A compounding pharmacies generally cannot use it to prepare patient prescriptions.
Q: Which peptides are still Category 2 as of mid-2026? A: Despite the February 2026 HHS announcement and the April 2026 reclassification path, several peptides remained on the Category 2 list pending formal FDA Federal Register action — most notably BPC-157, TB-500 (thymosin beta-4), KPV, MOTS-c, DSIP, epitalon, Selank, Semax, and melanotan-2 in some lists. Status can change with each Federal Register notice. Always check the current FDA list before relying on availability.
Q: Why has the FDA not moved every peptide back to Category 1? A: Each peptide is reviewed individually. Reclassification depends on the peptide's identity, purity, manufacturing track record, and the FDA's safety review of the published evidence. Some peptides have decades of animal data but limited human trials, which slows the review.
Disclaimer
As of May 2026, several peptides discussed in this article — including BPC-157, TB-500, KPV, MOTS-c, DSIP, epitalon, Selank, Semax, and melanotan-2 — are classified by the FDA as Category 2, which means they are not currently available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning these peptides to Category 1 pending formal FDA Federal Register notice. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
- FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A — Category 1.
- Federal Register. Food and Drug Administration agency notices.
This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health's published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What does Category 2 mean for peptide access?
Category 2 means a substance has been nominated for the FDA's 503A bulk drug substance list but the FDA has identified concerns about safety or effectiveness that require further review. While a peptide sits in Category 2, 503A compounding pharmacies generally cannot use it to prepare patient prescriptions.
Which peptides are still Category 2 as of mid-2026?
Despite the February 2026 HHS announcement and the April 2026 reclassification path, several peptides remained on the Category 2 list pending formal FDA Federal Register action — most notably BPC-157, TB-500 (thymosin beta-4), KPV, MOTS-c, DSIP, epitalon, Selank, Semax, and melanotan-2 in some lists. Status can change with each Federal Register notice. Always check the current FDA list before relying on availability.
Why has the FDA not moved every peptide back to Category 1?
Each peptide is reviewed individually. Reclassification depends on the peptide's identity, purity, manufacturing track record, and the FDA's safety review of the published evidence. Some peptides have decades of animal data but limited human trials, which slows the review.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.